TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinu...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Irela...
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )
7 Oct 2019
Lutetium-177 PSMA scanning for prostate cancer
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Lutetium-177 PSMA scanning for prostate cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Optimal timing of radiotherapy following radical prostatectomy
Prof Chris Parker - The Royal Marsden Hospital, London, UK
Optimal timing of radiotherapy following radical prostatectomy ( Prof Chris Parker - The Royal Marsden Hospital, London, UK )
4 Oct 2019
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019